查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2004001

乳糜泻治疗市场：2026年至2032年全球市场预测（依治疗方法、药物类别、给药途径、通路、剂型、最终用户、年龄层和适应症阶段划分）

Celiac Disease Drugs Market by Therapy Type, Drug Class, Route Of Administration, Distribution Channel, Dosage Form, End User, Age Group, Indication Stage - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，乳糜泻治疗市场价值将达到 17.3 亿美元，到 2026 年将成长到 19 亿美元，到 2032 年将达到 35.9 亿美元，复合年增长率为 10.96%。

主要市场统计数据
基准年 2025 17.3亿美元
预计年份：2026年 19亿美元
预测年份 2032 35.9亿美元
复合年增长率 (%) 10.96%

本书精彩地说明了不断变化的治疗和商业格局，以及这些格局如何影响乳糜泻治疗的发展。

乳糜泻的治疗模式已从主要依赖饮食管理转变为以分子生物学、免疫学和药学进步为驱动的蓬勃发展的治疗领域。这种转变提升了临床目标，从透过避免麸质来控制症状，转向改善潜在的疾病机制、促进黏膜癒合和减少长期併发症。因此，包括製药业、临床医生和保险公司在内的相关人员，如今正从兼顾临床意义与实际应用和报销情况的观点来评估各种机会。

重塑乳糜泻疗法临床开发、交付模式和商业化路径的变革性变化策略概述

在治疗领域，多种趋同的转变正在发生，重塑研发人员和医疗保健系统的优先事项。首先，作用机制正加速多样化。旨在分解摄取麸质的酶疗法、旨在抑制抗原特异性免疫反应的靶向免疫调节剂以及靶向微生物组的益生菌，都基于不同的生物学原理。这种多方面的方法增加了差异化产品的可能性，但也使治疗方法的比较评估变得更加复杂。

对 2025 年美国关税政策变化对乳糜泻治疗药物的研发、生产和供应链的累积影响进行定性分析。

近期关税政策的变化进一步加剧了全球药品供应链的复杂性，其影响波及乳糜泻治疗药物研发、生产和分销的各个环节。活性药物成分和特殊辅料关税的提高，推高了新型生技药品和小分子製剂的上游工程投入成本。为此，相关企业正在重新评估其供应商组合，加快替代供应商的认证流程，并探索将生产环节转移到近岸地区或重建关键生产流程，以降低贸易波动带来的风险。

将治疗方法、药物分类、给药途径、分销、剂型、最终用户、年龄和适应症阶段等因素转化为策略重点的实用细分见解。

细分市场分析表明，不同类型的治疗方法——酶疗法、免疫调节疗法和益生菌疗法——之间存在差异，从而产生不同的临床价值提案和操作要求。酵素疗法优先考虑口服製剂的稳定性以及不受饮食环境影响的可预测活性。免疫调节剂需要复杂的安全性监测，在某些情况下还需要肠外给药途径。另一方面，益生菌则更注重菌株选择、储存管理和监管分类的细微差别。这些差异会影响研发进度、监管策略以及获得支付方核准所需的证据材料。

重点区域见解，比较美洲、欧洲、中东和非洲以及亚太地区的驱动因素、采用趋势和政策环境。

在美洲，完善的诊断基础设施、集中的胃肠病学专家以及充满活力的风险投资和生物技术生态系统，正推动差异化治疗方法的快速临床开发和早期商业化。该地区的支付方框架通常强调疗效比较和长期结果，倾向于选择具有明确且可证实益处的治疗方法。打入市场策略通常需要直接比较试验和真实世界结果的数据，以证明其高价定价和纳入处方药目录的合理性。

关注影响产品线优先排序、生产製造和市场进入决策的竞争与合作行为的企业级策略洞察。

乳糜泻治疗领域的主要企业正在推行差异化策略，将自主研发与策略合作结合。生物技术创新者通常专注于早期机制检验和市场定位，并利用目标临床终点进行概念验证（PoC）。同时，大型製药企业通常凭藉先进的生产技术、监管专业知识和成熟的商业网络，实现规模经济，在达成合作和许可协议后，加速后期研发并拓展市场。

为业界领导者提供切实可行的建议，以加速乳糜泻治疗药物的研发，优化药物取得途径，并建立稳健的商业化模式。

首先，我们透过将关键终点纳入试验设计并儘早规划真实世界数据（RWE）的收集，使临床开发与支付者和患者的优先事项保持一致。这种方法缩小了监管核准与支付方接受度之间的差距，并强化了支持有利报销的价值提案。其次，我们透过认证多家关键原料供应商、探索区域生产方案以及设计尽可能减少对低温运输依赖的剂型，实现供应链多元化并降低风险。这些措施降低了关税和物流方面的风险，并提高了对需求波动的应对力。

对用于得出可靠且可操作的乳糜泻治疗见解的调查方法进行透明的概述。

本研究整合了第一手资料和第二手资料，全面概述了治疗、商业和监管方面的趋势。第一手资料包括与相关人员（包括临床医生、保险公司代表、供应链专家、业务拓展经理和患者权益组织）进行结构化访谈和讨论，以收集关于未满足需求、推广障碍和证据要求的真实观点。第二手资料则係统地回顾了同行评审文献、临床试验註册信息、监管指南和公开的企业资讯披露，以阐明发展趋势和监管预期。

简洁的结论整合了对希望了解和主导乳糜泻治疗发展趋势的利害关係人的策略意义。

乳糜泻的治疗格局正日趋成熟，成为一个多方面的生态系统，其中基于机制的创新与复杂的商业性和营运现实相互交织。研发人员必须平衡科学抱负与实际考量，例如生产要求、给药途径的权衡、通路以及支付方驱动的证据要求，才能将临床潜力转化为患者可及性。供应链和政策的发展，包括关税相关的变化，也为制定具韧性的研发和商业化策略带来了更多挑战。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗方法分類的乳糜泻治疗市场

  • 酵素疗法
  • 免疫调节疗法
  • 益生菌疗法

第九章 乳糜泻治疗市场：依药物类别划分

  • 生物製药
  • 低分子化合物

第十章：乳糜泻治疗市场：依给药途径划分

  • 注射药物
  • 口服

第十一章 乳糜泻治疗市场：依通路划分

  • 医院药房
    • 私立医院
    • 公立医院
  • 网路药房
  • 零售药房
    • 连锁药局
    • 独立经营药房

第十二章：按剂型分類的乳糜泻治疗药物市场

  • 注射药物
  • 口服
    • 胶囊
    • 药片

第十三章 乳糜泻治疗市场：依最终使用者划分

  • 居家医疗环境
    • 由护理师管理
    • 自我管理
  • 医院
  • 专科诊所
    • 胃肠病诊所
    • 一般诊所

第十四章 乳糜泻治疗市场：依年龄组别划分

  • 成人
  • 儿童

第十五章：依适应症阶段分類的乳糜泻治疗市场

  • 急性期管理
  • 维持治疗

第十六章 乳糜泻治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章 乳糜泻治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章 乳糜泻治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章：美国乳糜泻治疗市场

第二十章：中国乳糜泻治疗市场

第21章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Adaptive Biotechnologies Corporation
  • Amyra Biotech AG
  • Anokion SA
  • Avaxia Biologics, Inc.
  • Calypso Biotech BV
  • Chugai Pharmaceutical Co., Ltd.
  • Entero Therapeutics, LLC
  • Equillium, Inc.
  • GlaxoSmithKline plc
  • ImmusanT, Inc.
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Precigen, Inc.
  • Protagonist Therapeutics, Inc.
  • Provention Bio, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Topas Therapeutics GmbH
  • Zedira GmbH
Product Code: MRR-4659C87123C2

The Celiac Disease Drugs Market was valued at USD 1.73 billion in 2025 and is projected to grow to USD 1.90 billion in 2026, with a CAGR of 10.96%, reaching USD 3.59 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.73 billion
Estimated Year [2026] USD 1.90 billion
Forecast Year [2032] USD 3.59 billion
CAGR (%) 10.96%

Compelling contextual introduction to the evolving therapeutic and commercial environment shaping celiac disease drug development

Celiac disease has transitioned from a predominantly dietary management paradigm to a vibrant therapeutic landscape driven by advances in molecular biology, immunology, and formulation science. This shift has elevated the clinical ambition from symptom control through gluten avoidance to modifying underlying disease mechanisms, improving mucosal healing, and reducing long-term complications. As a result, stakeholders across industry, clinical practice, and payers now evaluate opportunities through a lens that balances clinical meaningfulness with practical delivery and reimbursement realities.

Concurrently, patient expectations are evolving. Increased awareness, improved diagnostic algorithms, and organized patient advocacy have amplified demand for therapies that reduce daily burden and provide measurable improvements in quality of life. Healthcare delivery is adapting to accommodate novel modalities and administration settings, while regulators and payers refine frameworks to assess comparative benefit and long-term value. Taken together, these factors create a complex, dynamic environment where therapeutic innovation must be clinically robust, commercially viable, and operationally executable to achieve adoption.

Strategic overview of the transformative shifts reordering clinical development, delivery models, and commercialization pathways in celiac disease therapeutics

The therapeutic landscape is experiencing multiple convergent shifts that are reshaping priorities for developers and healthcare systems. First, mechanistic diversification has accelerated: enzyme therapies aimed at degrading ingested gluten, targeted immunomodulators designed to blunt antigen-specific immune responses, and microbiome-directed probiotics each pursue distinct biological rationales. This pluralistic approach increases the probability of differentiated products while complicating comparative assessments across modalities.

Second, modality and molecule innovations have altered clinical trial design and regulatory engagement. Biologic agents and engineered small molecules require distinct manufacturing, stability, and delivery considerations, which affects timelines and capital intensity. Hybrid development strategies that pair oral formulations with targeted biologic adjuncts are emerging to reconcile efficacy with patient convenience. Third, distribution and care delivery models are evolving. Expansion of online prescription services and the maturation of homecare administration pathways are changing how therapies reach patients and how adherence is monitored, thereby influencing commercial models and payer interactions.

Finally, collaborative ecosystems are maturing; strategic partnerships between biotech innovators, contract development manufacturers, specialty pharmacies, and clinical networks are becoming essential. These alliances accelerate access to specialized capabilities, mitigate operational risk, and enable more flexible commercialization strategies that align with diverse routes of administration and end-user settings.

Qualitative analysis of the cumulative impacts of United States tariff policy shifts in 2025 on celiac disease drug development, manufacturing, and supply chains

Recent tariff policy changes have introduced added complexity to global pharmaceutical supply chains, with implications that ripple through development, manufacturing, and distribution of celiac disease therapies. Increased tariffs on active pharmaceutical ingredients and specialized excipients have raised upstream input costs for both novel biologics and small molecule formulations. In response, sponsors are reassessing supplier portfolios, accelerating qualification of alternative vendors, and evaluating nearshoring or repatriation of critical manufacturing steps to reduce exposure to trade-driven volatility.

These shifts also influence strategic decisions around clinical sourcing and manufacturing scale-up. Companies conducting multinational clinical trials face higher logistics costs for investigational product movement and sample transport, which can increase protocol complexity and necessitate greater contingency planning. Moreover, tariffs can affect choices of final dosage form and route of administration; therapies that rely on specialized injectable delivery systems or cold-chain dependent biologics may be disproportionately impacted compared with stable oral formulations.

Payers and procurement entities are also adjusting contracting expectations in light of cost pressures, prompting manufacturers to strengthen value propositions and explore risk-sharing arrangements. Overall, the tariff landscape encourages a multi-pronged response that includes supply chain diversification, strategic localization of critical processes, prioritization of cost-efficient dosage forms, and intensified negotiation with downstream distribution partners to preserve access and affordability.

Actionable segmentation insights that translate therapy, drug class, route, distribution, dosage form, end-user, age, and indication stage considerations into strategic priorities

Segmentation reveals that therapy type distinctions-enzyme therapy, immunomodulator therapy, and probiotic therapy-create discrete clinical value propositions and operational requirements. Enzyme therapies prioritize robust oral formulation stability and predictable activity across dietary contexts, immunomodulators demand sophisticated safety monitoring and potentially parenteral administration pathways, while probiotics emphasize strain selection, shelf-life management, and regulatory classification nuances. These differences influence development timelines, regulatory strategy, and the evidence package required for payer acceptance.

Drug class segmentation into biological and small molecule categories further determines manufacturing complexity and supply chain risk. Biologicals typically require specialized facilities, cold-chain logistics, and higher capital intensity, whereas small molecules offer more established manufacturing routes and potentially broader oral dosing flexibility. Route of administration segmentation between injectable and oral options affects patient adherence, site-of-care considerations, and reimbursement models; oral therapies favor self-administration and broader outpatient access, while injectables may necessitate clinic- or home-based nurse involvement.

Distribution channel segmentation across hospital pharmacies, online pharmacies, and retail pharmacies highlights commercially relevant access routes. Hospital pharmacies, encompassing private and public hospitals, remain critical for acute and specialty clinic-dispensed biologics, while online pharmacies, including OTC and prescription services, enable broader geographic reach and convenience. Retail pharmacies, both chain and independent, support chronic maintenance therapies and front-line patient engagement. Dosage form segmentation-injectable formulation, oral capsules, oral tablets, and powder form-maps directly to stability, adherence, and manufacturing trade-offs that influence pricing and shelf-life strategies.

End-user segmentation into homecare settings, hospitals, and specialty clinics clarifies care pathways. Homecare, whether nurse assisted administration or self-administration, supports long-term maintenance therapies and reduces hospital burden, whereas hospital and specialty clinic settings remain central for acute management and complex immunomodulatory regimens. Age group segmentation, distinguishing adults and pediatrics, requires tailored safety, dosing, and formulation approaches, with pediatric development often demanding dedicated trials and formulations. Finally, indication stage segmentation between acute management and maintenance therapy shapes the evidence hierarchy needed for regulatory approval and payer reimbursement, with acute interventions often evaluated on rapid clinical endpoints and maintenance therapies judged on durability and long-term outcomes.

Key regional insights that compare drivers, adoption dynamics, and policy environments across the Americas, Europe Middle East & Africa, and Asia-Pacific regions

In the Americas, strong diagnostic infrastructure, concentrated centers of gastroenterology expertise, and an active venture and biotech ecosystem drive rapid clinical development and early commercialization of differentiated therapies. Payer frameworks in this region often emphasize comparative effectiveness and long-term outcomes, which favors therapies with clear demonstrable benefits. Market access strategies frequently require head-to-head evidence or real-world outcomes data to support premium pricing and formulary placement.

Europe, the Middle East & Africa presents a heterogeneous landscape where single-payer and multi-payer systems contrast with regions that have limited specialist access. Regulatory pathways in Europe value comprehensive safety data and often incorporate health technology assessment into reimbursement decisions. In several markets, centralized procurement and stringent price negotiation practices encourage manufacturers to develop strong health economic models and engage early with regional health authorities to align clinical development with reimbursement expectations.

Asia-Pacific exhibits rapid adoption potential driven by expanding diagnostics, growing specialty care capacity, and increasing public and private investment in biotechnology. However, regulatory environments vary widely, and manufacturers often need tailored development and commercialization roadmaps that account for local registration requirements, differential reimbursement mechanisms, and diverse distribution ecosystems. Across all regions, collaboration with local clinical networks, investment in real-world evidence generation, and adaptive pricing or access programs enhance the likelihood of successful adoption.

Strategic company-level insights highlighting the competitive and collaborative behaviors shaping pipeline prioritization, manufacturing, and market entry decisions

Leading organizations in the celiac disease therapeutic arena are pursuing differentiated strategies that combine internal development with strategic partnerships. Biotech innovators often concentrate on early-stage mechanistic validation and niche positioning, leveraging targeted clinical endpoints to demonstrate proof of concept. Larger pharmaceutical firms typically bring scale through advanced manufacturing, regulatory expertise, and established commercial networks, enabling accelerated late-stage development and broader market rollout when partnerships or licensing agreements align.

Across the sector, companies are investing in capabilities that de-risk production and improve time-to-market. This includes contract manufacturing relationships for biologics and small molecules, specialized formulation expertise for oral and powder forms, and digital health integrations for adherence and outcome tracking. Competitive dynamics are also driving consolidation of complementary assets, whether through asset acquisitions, co-development deals, or joint commercialization agreements. This collaborative approach helps distribute risk, pool resources for expensive late-stage trials, and harmonize clinical data packages for multinational submissions.

Finally, companies that succeed most consistently are those that integrate clinical differentiation with pragmatic commercialization planning-aligning evidence generation to payer expectations, building scalable manufacturing networks, and designing patient-centric delivery models that work across inpatient, specialty clinic, and homecare channels.

Actionable recommendations for industry leaders to accelerate development, optimize access, and build resilient commercialization models for celiac therapies

First, align clinical development with payer and patient priorities by embedding outcomes that matter into trial design and by planning real-world evidence generation early. This approach reduces the gap between regulatory approval and payer acceptance and enhances the value narrative that supports favorable reimbursement. Second, diversify and de-risk supply chains by qualifying multiple suppliers for critical inputs, exploring regional manufacturing options, and designing dosage forms that minimize cold-chain dependence when clinically feasible. These steps mitigate tariff and logistics vulnerabilities and improve responsiveness to demand shifts.

Third, pursue adaptive commercialization strategies that leverage online prescription services and retail networks for maintenance therapies while reserving hospital and specialty clinic pathways for complex immunomodulatory regimens. Coupling product launch plans with tailored patient support programs can enhance adherence and real-world outcomes. Fourth, prioritize strategic collaborations-partner with contract development organizations, specialty pharmacies, and clinical networks to access technical capabilities and accelerate market entry. Finally, invest in patient-centric formulation development and pediatric-friendly dosing options to broaden addressable populations and reduce barriers to adoption across care settings.

Transparent overview of the research methodology employed to generate robust, actionable insights into celiac disease therapeutics

This research synthesized primary and secondary inputs to develop a comprehensive understanding of therapeutic, commercial, and regulatory dynamics. Primary research consisted of structured interviews and discussions with stakeholders including clinicians, payer representatives, supply chain experts, business development leaders, and patient advocacy groups to capture real-world perspectives on unmet needs, adoption barriers, and evidence requirements. Secondary research included a systematic review of peer-reviewed literature, clinical trial registries, regulatory guidelines, and publicly available company disclosures to contextualize development trends and regulatory expectations.

Analytical methods integrated qualitative synthesis with cross-validation across data sources to ensure robustness. Segmentation frameworks were applied to interpret findings across therapy type, drug class, route of administration, distribution channel, dosage form, end-user, age group, and indication stage. Regional analyses considered regulatory, payer, and delivery system heterogeneity. The methodology emphasized triangulation of evidence, scenario-based assessment of policy impacts, and the translation of technical findings into actionable strategic recommendations for stakeholders.

Concise conclusion that synthesizes strategic implications for stakeholders seeking to navigate and lead in the evolving celiac disease therapeutic landscape

The celiac disease therapeutic landscape is maturing into a multifaceted ecosystem where mechanistic innovation intersects with complex commercial and operational realities. Developers must balance scientific ambition with pragmatic considerations-manufacturing requirements, route-of-administration trade-offs, distribution pathways, and payer evidence demands-to convert clinical promise into patient access. Supply chain and policy developments, including tariff-related shifts, add further imperatives to design resilient development and commercialization strategies.

Success will favor organizations that integrate rigorous clinical differentiation with flexible operational models, that engage early with payers and clinicians to align evidence generation with value expectations, and that build partnerships to complement internal capabilities. By pursuing patient-centric formulation strategies, diversifying supply chains, and tailoring commercialization to regional idiosyncrasies, stakeholders can improve the odds of achieving both clinical impact and sustainable access for new celiac disease therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Celiac Disease Drugs Market, by Therapy Type

  • 8.1. Enzyme Therapy
  • 8.2. Immunomodulator Therapy
  • 8.3. Probiotic Therapy

9. Celiac Disease Drugs Market, by Drug Class

  • 9.1. Biological
  • 9.2. Small Molecule

10. Celiac Disease Drugs Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral

11. Celiac Disease Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
    • 11.1.1. Private Hospital
    • 11.1.2. Public Hospital
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Celiac Disease Drugs Market, by Dosage Form

  • 12.1. Injectable Formulation
  • 12.2. Oral
    • 12.2.1. Capsules
    • 12.2.2. Tablets

13. Celiac Disease Drugs Market, by End User

  • 13.1. Homecare Settings
    • 13.1.1. Nurse Assisted Administration
    • 13.1.2. Self Administration
  • 13.2. Hospitals
  • 13.3. Specialty Clinics
    • 13.3.1. Gastroenterology Clinics
    • 13.3.2. General Clinics

14. Celiac Disease Drugs Market, by Age Group

  • 14.1. Adults
  • 14.2. Pediatrics

15. Celiac Disease Drugs Market, by Indication Stage

  • 15.1. Acute Management
  • 15.2. Maintenance Therapy

16. Celiac Disease Drugs Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Celiac Disease Drugs Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Celiac Disease Drugs Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Celiac Disease Drugs Market

20. China Celiac Disease Drugs Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Adaptive Biotechnologies Corporation
  • 21.6. Amyra Biotech AG
  • 21.7. Anokion SA
  • 21.8. Avaxia Biologics, Inc.
  • 21.9. Calypso Biotech BV
  • 21.10. Chugai Pharmaceutical Co., Ltd.
  • 21.11. Entero Therapeutics, LLC
  • 21.12. Equillium, Inc.
  • 21.13. GlaxoSmithKline plc
  • 21.14. ImmusanT, Inc.
  • 21.15. Johnson & Johnson Services, Inc.
  • 21.16. Pfizer Inc.
  • 21.17. Precigen, Inc.
  • 21.18. Protagonist Therapeutics, Inc.
  • 21.19. Provention Bio, Inc.
  • 21.20. Sanofi S.A.
  • 21.21. Takeda Pharmaceutical Company Limited
  • 21.22. Topas Therapeutics GmbH
  • 21.23. Zedira GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELIAC DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CELIAC DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ENZYME THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY IMMUNOMODULATOR THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PROBIOTIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY BIOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INJECTABLE FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY NURSE ASSISTED ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SELF ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GASTROENTEROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY ACUTE MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 236. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 237. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 238. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 239. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. GCC CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 272. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 278. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 279. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 280. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 281. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 284. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. G7 CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 286. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 289. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 292. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 293. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 294. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 295. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 297. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 298. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 299. NATO CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 300. GLOBAL CELIAC DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA CELIAC DISEASE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA CELIAC DISEASE DRUGS MARKET SIZE, BY INDICATION STAGE, 2018-2032 (USD MILLION)